Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Affimed NV AFMD

Healthcare Biotechnology
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1... see more

Recent & Breaking News (NDAQ:AFMD)

15 Biggest Mid-Day Gainers For Friday

Benzinga.com  July 14, 2017

Affimed Presents Preclinical Data on AFM24 and AFM26 at EACR-AACR-SIC 2017

GlobeNewswire June 27, 2017

Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017

GlobeNewswire June 6, 2017

Affimed to Present at the Jefferies 2017 Global Healthcare Conference - New York

GlobeNewswire May 30, 2017

Affimed Announces Annual General Meeting of Shareholders

GlobeNewswire May 22, 2017

Affimed to Present Immune Cell Engager Data at ASCO Annual Meeting and EACR-AACR-SIC Special Conference

GlobeNewswire May 17, 2017

Affimed Reports Financial Results for First Quarter 2017

GlobeNewswire May 17, 2017

Affimed Announces First Quarter 2017 Financial Results and Corporate Update Conference Call

GlobeNewswire May 10, 2017

Affimed Presents Data on Immune Cell Engager Pipeline at the AACR Annual Meeting 2017

GlobeNewswire April 5, 2017

Affimed Reports Financial Results for Fourth Quarter and Year End 2016

GlobeNewswire March 30, 2017

Affimed Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Conference Call

GlobeNewswire March 23, 2017

Affimed to Present at the Oppenheimer 27th Annual Healthcare Conference - New York

GlobeNewswire March 15, 2017

Affimed to Present at the Oppenheimer 27th Annual Healthcare Conference - New York

GlobeNewswire March 14, 2017

Affimed to Present Data on Immune Cell Engagers at the AACR Annual Meeting 2017

GlobeNewswire March 1, 2017

Affimed to Present at the Cowen and Company 37th Annual Health Care Conference

GlobeNewswire February 28, 2017

Affimed to Present at the Leerink Partners 6th Annual Global Healthcare Conference

GlobeNewswire February 8, 2017

First Clinical Milestone Achieved in Collaboration between AbCheck and Lilly

GlobeNewswire January 31, 2017

Affimed Announces Closing of Public Offering of Common Stock

GlobeNewswire January 25, 2017

15 Biggest Mid-Day Losers For Friday

Benzinga.com  January 20, 2017

Mid-Day Market Update: Crude Oil Up 2.8%; Bristol-Myers Squibb Shares Slide After Opdivo Decision

Benzinga.com  January 20, 2017